ADAG•benzinga•
Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga